Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03720574
Recruitment Status : Suspended (Reassess safety risks and benefits)
First Posted : October 25, 2018
Last Update Posted : April 13, 2020
Sponsor:
Information provided by (Responsible Party):
Kanion & Huawe Medicine Co.,Ltd

Brief Summary:
The purpose of this study is to assess the safety and weight loss effect of lorcaserin at the end of the first year of treatment (Week 48) in overweight and Chinese adult obese patients compared to placebo.

Condition or disease Intervention/treatment Phase
Obesity Drug: Lorcaserin 10 mg BID Drug: Matching Placebo BID Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Adult Obese Patients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Actual Study Start Date : September 17, 2019
Estimated Primary Completion Date : December 6, 2020
Estimated Study Completion Date : July 6, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Lorcaserin

Arm Intervention/treatment
Experimental: Lorcaserin 10 mg BID
Lorcaserin 10 mg tablet each morning and evening
Drug: Lorcaserin 10 mg BID
Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks

Placebo Comparator: Matching Placebo BID
Matching Placebo tablet each morning and evening
Drug: Matching Placebo BID
Matching Placebo tablet each morning and evening for a duration of 48 weeks




Primary Outcome Measures :
  1. 5% responders [ Time Frame: 48 weeks ]
    Proportion (%) of subjects who lose at least 5% of their baseline body weight at week 48


Secondary Outcome Measures :
  1. Weight change [ Time Frame: 48 weeks ]
    Change from baseline in body weight (kilograms) at week 48

  2. 10% responders [ Time Frame: 48 weeks ]
    Proportion (%) of subjects who lose at least 10% of their baseline body weight at week 48

  3. circumference and hip circumference change [ Time Frame: 48 weeks ]
    Change from baseline in waist circumference and hip circumference (centimeters) at week 48

  4. Blood Pressure change [ Time Frame: 48 weeks ]
    Change from baseline in waist systolic/ diastolic blood pressure (mmHg) at week 48

  5. Lipids change [ Time Frame: 48 weeks ]
    Change from baseline in Lipids (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides) (mmol/L) at week 48

  6. CV Risk Markers change [ Time Frame: 48 weeks ]
    Change from baseline in CV Risk Markers (CRP in μg/L, fibrinogen in g/L) at week 48

  7. Glucose and HbA1c change [ Time Frame: 48 weeks ]
    Change from baseline in fasting glucose (mmol/L) and HbA1c (%) at week 48

  8. IWQOL-LITE score change [ Time Frame: 48 weeks ]
    Change from baseline in IWQOL-LITE score at week 48



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or females aged from 18 to 65 years (inclusive).
  • Able to walk and preform exercise program required by trial protocol.
  • Body Mass Index (BMI) within the range of 30 to 45 kg/m2 (obese) with or without co-morbid conditions or greater than or equal to 27 and less than 30 kg/m2 (overweight) with at least one treated or untreated comorbid condition (hypertension, dyslipidemia, cardiovascular disease, untreated abnormal glucose metabolism, sleep apnea). For untreated co-morbid conditions, the condition must be considered by the Investigator as clinically stable.
  • Prior to the study, patients should be able to voluntarily participate in this study and sign informed consent form approved by IRB/ICE

Exclusion Criteria:

  • Not suitable to participate in the study in the opinion of the Investigator, including an existing physical or mental condition that prevents compliance with the protocol.
  • Patients who had a history of Type 1 diabetes mellitus or confirmed diagnosis of Type 2 diabetes mellitus for more than 6 months.
  • Recent history (within 1 years before entering the study) of major depression, anxiety, or other psychiatric disease requiring treatment with prescription medication (e.g., SSRI's, SNRI's [including buproprion], tricyclics, antipsychotics, lithium). Use of SSRI's and SNRI's (including buproprion) for reasons other than active psychiatric indications (e.g., migraine, weight loss, smoking cessation) must meet a 3-month washout.
  • Total score on the Beck Depression Inventory-II (BDI-II) > 20.
  • Binge Eating Scale score >17.
  • History of epilepsy or other seizure disorder.
  • Has done or anticipate Surgical procedure for the treatment of obesity (i.e., gastric bypass, gastric banding).
  • Anticipation of surgery during the study period that may interfere with completion or compliance with the protocol.
  • Uncontrolled hypertension after certain treatments, defined as systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥ 100 mmHg.
  • History of valve replacement surgery or CABG or other invasive cardiovascular surgical procedure. A diagnostic cardiac catheterization does not exclude.
  • History of Myocardial infarction(MI), Cerebral Vascular Accident(CVA), or transient ischemic attack(TIA). Reversible ischemic neurological deficits (RIND), cardiac arrhythmia requiring medical or surgical treatment within 3 months of screening.
  • Major surgical procedure (intrathoracic, intracranial, intraperitoneal, liposuction) within 6 months of screening
  • History of unstable angina
  • History of congestive heart failure caused by insufficiency or stenosis of any heart valve
  • History of pulmonary artery hypertension
  • Symptomatic untreated congestive heart failure of any etiology (stably treated NYHA class I or II CHF of ischemic or hypertensive etiology is acceptable)
  • History of organ/bone marrow transplantation
  • Abnormal TSH lab value > 1.5x ULN
  • Hyperthyroidism, including abnormal screening lab values with FT4 > ULN and TSH < LLN.
  • Fasting triglycerides > 499 mg/dL(5.64 mmol/L) ,if elevated at Screening, but not on a subsequent re-check, patient will be eligible. Otherwise, patients can't be enrolled.
  • LDL-cholesterol ≥ 190 mg/dL(4.92 mmol/L).
  • HbA1c greater than 9.0%
  • Fasting glucose > 270 mg/dL(11.0 mmol/L) ,if elevated at Screening, but not on a subsequent re-check, patient will be eligible. Otherwise, patients can't be enrolled.
  • Clinically significant abnormal hepatic (e.g., AST or ALT > 2.5x ULN, or total bilirubin > 1.5x ULN) or renal function lab tests (e.g., creatinine > 1.25x ULN) suggestive of hepatic or renal impairment.
  • Positive result of HIV, hepatitis B or hepatitis C screens.
  • Malignancy within 5 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins).
  • Treatment with over-the counter weight loss products or appetite suppressants (including herbal weight loss agents) within 1 month of the screening visit, or with a prescription anti-obesity drug (phentermine, sibutramine, orlistat) or lipid dissolving injections within 3 months.
  • Over 3 days of treatment with oral or parenteral corticosteroids within 2 weeks of the screening visit.
  • Recent history (within 2 years prior to the screening visit) of alcohol or drug abuse.
  • Significant change in smoking habits within 3 months prior to screening.
  • Participated in any clinical study with an investigational drug, biologic, or device within 3 month prior to screening.
  • Significant change in diet or level of physical activity or change in weight of > 5 kg within 3 month prior to screening.
  • Use of liquid weight loss diet within 6 months prior to screening.
  • Disagree to continue to use an accepted method of birth control during and for at least 3 months after last study medication administration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03720574


Locations
Layout table for location information
China, Anhui
Bengbu Medical College First Affiliated Hospital
Bengbu, Anhui, China, 233000
China, Beijing
Peking University First Hospital
Beijing, Beijing, China, 100034
China, Henan
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China, 471003
China, Hunan
Xiangtan Central Hospital
Xiangtan, Hunan, China, 411100
China, Jiangsu
Second Hospital of Changzhou
Changzhou, Jiangsu, China, 213119
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210011
China, Liaoning
Jinzhou Central Hospital
Jinzhou, Liaoning, China, 121000
China, Shandong
Jinan Center Hospital
Jinan, Shandong, China, 250013
China, Shanghai
Shanghai East Hospital
Shanghai, Shanghai, China
Sponsors and Collaborators
Kanion & Huawe Medicine Co.,Ltd
Investigators
Layout table for investigator information
Principal Investigator: Xiaohui Guo, Ph. D Peking University First Hospital
Layout table for additonal information
Responsible Party: Kanion & Huawe Medicine Co.,Ltd
ClinicalTrials.gov Identifier: NCT03720574    
Other Study ID Numbers: LWY17016C
First Posted: October 25, 2018    Key Record Dates
Last Update Posted: April 13, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Kanion & Huawe Medicine Co.,Ltd:
Overweight or Obesity Management
Behavioral Modification
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Overweight
Overnutrition
Nutrition Disorders
Body Weight
Signs and Symptoms